DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Denali Therapeutics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$18.04+0.43 (+2.44%)

Close on Oct 19, 2026

Market cap: $3.38B
P/E (TTM): –
Dividend yield: –

Denali Therapeutics Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31	Q3 2022 2022-09-30	Q2 2022 2022-06-30	Q1 2022 2022-03-31	Q4 2021 2021-12-31	Q3 2021 2021-09-30	Q2 2021 2021-06-30	Q1 2021 2021-03-31	Q4 2020 2020-12-31	Q3 2020 2020-09-30	Q2 2020 2020-06-30	Q1 2020 2020-03-31	Q4 2019 2019-12-31	Q3 2019 2019-09-30	Q2 2019 2019-06-30	Q1 2019 2019-03-31	Q4 2018 2018-12-31	Q3 2018 2018-09-30	Q2 2018 2018-06-30	Q1 2018 2018-03-31	Q4 2017 2017-12-31	Q3 2017 2017-09-30	Q2 2017 2017-06-30	Q1 2017 2017-03-31
Depreciation & Amortization	3.57	2.85	2.87	2.95	3.05	2.33	1.85	1.84	1.94	2.16	2.18	2.22	2.29	10	4.09	2.14	2.07	2.08	2.09	2.19	2.20	2.11	2.12	2.16	2.15	2.11	2.06	1.89	1.64	2.40	2.38	2.33	1.86	0.85	–	–	–	–
Stock-Based Compensation	23	23	24	25	25	25	25	25	25	28	26	27	27	28	25	25	24	26	22	21	21	21	14	13	12	11	8.89	8.90	14	6.87	5.65	5.51	4.71	2.93	1.46	1.13	1.06	0.77
Other Non-Cash Items	0.52	-0.29	–	–	0	0	–	–	–	–	0.00	0	–	–	-0.01	-0.05	-0.01	0	0	0	0.00	0.00	-0.02	-0.06	-0.01	0.05	-0.08	0.11	0.31	0	0.04	0	–	–	–	–	–	–
Change in Accounts Payable	0.23	3.88	-3.41	-4.07	2.60	-2.64	1.29	-4.37	3.89	0.64	-2.08	-3.96	4.77	3.70	-1.72	1.90	0.84	1.25	-0.08	0.78	2.38	0.62	-1.77	0.89	-0.45	-0.29	0.57	-0.84	-0.66	1.97	-1.76	-5.86	8.05	-0.95	-0.11	0.76	0.27	-0.72
Change in Unearned Revenue	–	–	–	–	–	–	–	–	–	–	0	0	0	0	-0.02	-3.38	0	-28	-1.32	-4.43	-7.14	0.97	-1.33	-9.28	-5.58	-3.07	-3.49	-1.18	-0.84	-0.78	12	-1.20	-1.65	60	0	0	–	–
Operating Cash Flow	-97	-131	-99	-107	-75	-131	-84	-59	-91	-114	-99	-87	-113	-59	-73	-57	-43	-72	-65	-41	-54	-50	514	0.09	-43	-54	-48	-30	-43	-30	93	-35	-42	34	-18	-22	-18	-19
Capital Expenditures	-0.81	-2.47	-1.52	1.38	-4.28	-5.08	-5.09	-3.88	-4.79	-2.15	-2.24	-2.07	-5.85	-2.79	-4.85	-6.05	-2.89	-4.04	-3.05	-1.88	-0.77	-2.80	-1.20	-0.71	-0.32	-0.88	-2.77	-2.85	-10	-2.03	-1.44	-0.85	-0.57	-0.54	-1.07	-0.37	-0.57	-0.87
Purchase of Investments	-272	-123	-253	-51	0	-138	-174	-100	-122	-834	-414	-498	-378	-524	-487	-123	-141	-364	-231	-344	-384	-463	-598	-364	-170	-153	-151	-75	-34	-110	-157	-39	-34	-328	-133	-18	-11	-17
Sale & Maturity of Investments	197	220	275	107	162	162	351	198	225	383	489	601	552	434	364	144	233	251	194	293	483	441	232	153	140	141	196	127	108	104	97	85	65	27	39	35	34	33
Investing Cash Flow	-104	94	21	58	158	19	172	94	99	-453	73	101	168	-93	-128	15	89	-118	-41	-53	98	-25	-367	-212	-30	-13	42	49	64	-8.05	-61	45	31	-301	-95	17	22	15
Stock Issued	0	12	–	0	0	0	-499	0	0	499	0	0	0	0	–	–	–	–	0	0	0	0	0	0	0	194	0	0	0	0	-94	0	0	94	266	0	–	–
Financing Cash Flow	15	219	192	-0.78	1.62	-3.76	-4.17	-19	6.76	500	4.71	2.49	9.02	1.60	300	5.15	4.40	1.46	5.17	3.32	7.04	3.82	9.52	426	3.42	196	2.03	0.68	2.57	0.91	1.69	0.66	1.43	93	296	0.36	0.05	0.32
Net Change in Cash	-186	182	114	-50	84	-116	84	16	14	-67	-21	16	64	-150	99	-36	50	-189	-101	-91	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Free Cash Flow	-98	-134	-100	-106	-80	-137	-89	-63	-96	-116	-101	-89	-119	-62	-78	-63	-46	-76	-69	-43	-55	-53	513	-0.62	-44	-55	-50	-33	-53	-32	92	-36	-42	33	-19	-22	-18	-20
Income Taxes Paid	–	–	–	–	–	–	0	0	0	0	0.00	0	0	0.00	0.05	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -45.7%

Financial strength

Current ratio: 8.37
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 223.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 4.05
Dividend yield: –